AMENDMENTS TO THE CLAIMS

Claim 1 (currently amended) An enhanced bioavailable composition comprising a co-precipitate of cefuroxime axetil and a water-soluble excipient made by dissolving about 10 parts by weight pure crystalline cefuroxime axetil and about 1 part by weight of the excipient in a suitable solvent, and recovering the co-precipitate, said composition having a disintegration time of at least 10 to 30 minutes and having a dissolution as determined by U.S. Pharmacopoeia 23rd Edition, of about 65% to about 80% in 20 minutes and about 80% to over 90% in 60 minutes.

Claim 2 (cancelled)

Claim 3 (currently amended) ~~The composition of claim 1 comprising from~~ An enhanced bioavailable composition comprising a co-precipitate of cefuroxime axetil and a water-soluble excipient made by dissolving about 75% to about 95% by weight pure crystalline cefuroxime axetil and from about 5% to about 25% by weight water-soluble excipient in a suitable solvent, and recovering the co-precipitate, said composition having a disintegration time of at least 10 to 30 minutes and having a dissolution as determined by U.S. Pharmacopoeia 23rd Edition, of about 65% to about 80% in 20 minutes and about 80% to over 90% in 60 minutes.

Claim 4 (cancelled)

Claim 5 (currently amended) The composition of claim 1 or 3 wherein the water-soluble excipient is selected from the group consisting of povidone, hydroxy propyl cellulose, methycellulose, lactose, mannitol and sorbitol.

Claim 6 (currently amended) A process of production of the composition of claim 1 or 3 which comprises:

- dissolving the cefuroxime axetil and water-soluble excipient in a solvent or a mixture of solvents; and
- evaporating the solvent or solvents.

Claim 7 (previously amended) The process of claim 6 wherein acetone is used as solvent.

Claim 8 (previously amended) The process of claim 6 wherein the solvent or solvents are evaporated by spray-drying.

Claim 9 (currently amended) A pharmaceutical tablet comprising the composition according to claim 1 or 3.

Claim 10 (previously amended) The pharmaceutical tablet of claim 9 further comprising a disintegrant.

E1 Cont

Claim 11 (previously amended) The pharmaceutical tablet of claim 10 wherein the disintegrant is a water-insoluble cross-linked polymer.

Claim 12 (previously amended) The pharmaceutical tablet of claim 10 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, sodium starch glycolate and crospovidone.

Claim 13 (previously amended) The pharmaceutical tablet of claim 10 further comprising a lubricant.

Claim 14 (previously amended) The pharmaceutical tablet of claim 13 wherein the lubricant is stearic acid or a metallic stearate.

Claim 15 (currently amended): An enhanced bioavailable composition comprising a co-precipitate of cefuroxime axetil and sorbitol made by dissolving about 10 parts by weight pure crystalline cefuroxime axetil about 1 part by weight of and the sorbitol in a suitable solvent, and recovering the co-precipitate, said composition having a disintegration time of at least 10 to 30 minutes and having a dissolution as determined by U.S. Pharmacopoeia 23rd Edition, of about 65% to about 80% in 20 minutes and about 80% to over 90% in 60 minutes.

Claim 16 (cancelled)

Claim 17 (previously added) A process of production of the composition of claim 15 which comprises:

- dissolving the cefuroxime axetil and sorbitol in a solvent or a mixture of solvents; and

- evaporating the solvent or solvents.

Claim 18 (previously added) The process of claim 16 wherein acetone is used as solvent.

E1 Cont'd

Claim 19 (previously added) A pharmaceutical tablet comprising the composition according to claim 15.

Claim 20 (previously added) The pharmaceutical tablet of claim 19 further comprising a disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and crospovidone.